ENZ
Enzo Biochem
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
stock price surged significantly
ample liquidity
Revenue Plunges
RSI Oversold
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ENZ
Enzo Biochem, Inc.
A developer of diagnostic and therapeutic products, Enzo Biochem focuses on molecular diagnostics, cancer research, and personalized medicine, with a portfolio of proprietary technologies
Life Science Tools and Services
Invalid Date
12/16/1999
New York Stock Exchange
125
07-31
Common stock
21 Executive Blvd., Farmingdale, NY 11735
--
Founded in New York, Enzo Biochem, Inc., has been operating as a life sciences company for more than 45 years. The company's current main business is through its life sciences division, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, detection, biochemicals and proteins. The company's proprietary products and technologies play a central role in translational research and drug development, including cell biology, genomics, detection, immunohistochemistry and small molecule chemistry.
Company Financials
EPS
ENZ has released its 2025 Q2 earnings. EPS was reported at -0.02, versus the expected 0.00, missing expectations. The chart below visualizes how ENZ has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ENZ has released its 2025 Q2 earnings report, with revenue of 7.33M, reflecting a YoY change of -14.25%, and net profit of -1.54M, showing a YoY change of 49.85%. The Sankey diagram below clearly presents ENZ’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
